Congresses
Transthyretin Amyloidosis (ATTR)
Peripheral Nerve Society (PNS) 2026
Transthyretin Amyloidosis (ATTR)
Heart Failure Association (HFA) 2026
Transthyretin Amyloidosis (ATTR)
American Academy of Neurology (AAN) 2026
Transthyretin Amyloidosis (ATTR)
American College of Cardiology (ACC) 2026
Transthyretin Amyloidosis (ATTR)
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2025
Transthyretin Amyloidosis (ATTR)
American Heart Association (AHA) 2025
Publications
Transthyretin Amyloidosis (ATTR)
Vutrisiran-Mediated Knockdown of Transthyretin in Patients with ATTR Amyloidosis
Clinical Pharmacokinetics
Transthyretin Amyloidosis (ATTR)
Vutrisiran in East Asian Patients With Transthyretin Amyloidosis With Cardiomyopathy: Post-Hoc Analysis of HELIOS-B
JACC: Asia
Transthyretin Amyloidosis (ATTR)
Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy and Renal Impairment: Analyses From HELIOS-B
Journal of Cardiac Failure
Transthyretin Amyloidosis (ATTR)
Best Practices and Key Barriers for Amyloidosis Patient Care at US Specialized Amyloidosis Centers: An Analysis by ARC-ASPIRE
Clinical Medicine Insights: Cardiology
Transthyretin Amyloidosis (ATTR)
Effect of vutrisiran on components of health status in transthyretin amyloidosis with cardiomyopathy: the HELIOS-B study
European Journal of Heart Failure
Transthyretin Amyloidosis (ATTR)
Efficacy and Safety of Vutrisiran in Patients with Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy: Analysis of the East Asian Subpopulation from HELIOS-A
Neurology and Therapy
